FMTX [NASD]
Forma Therapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-4.00 Insider Own0.90% Shs Outstand47.81M Perf Week0.10%
Market Cap954.13M Forward P/E- EPS next Y-3.67 Insider Trans0.00% Shs Float45.40M Perf Month57.50%
Income-190.20M PEG- EPS next Q-1.08 Inst Own88.80% Short Float2.72% Perf Quarter175.80%
Sales- P/S- EPS this Y-13.60% Inst Trans0.16% Short Ratio0.92 Perf Half Y102.44%
Book/sh8.67 P/B2.30 EPS next Y12.60% ROA-35.30% Target Price20.60 Perf Year-15.19%
Cash/sh8.27 P/C2.41 EPS next 5Y- ROE-39.70% 52W Range4.95 - 24.99 Perf YTD40.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.21% Beta-
Dividend %- Quick Ratio12.70 Sales past 5Y- Gross Margin- 52W Low302.83% ATR0.41
Employees189 Current Ratio12.70 Sales Q/Q- Oper. Margin- RSI (14)86.67 Volatility0.30% 1.11%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.50% Profit Margin- Rel Volume0.55 Prev Close19.91
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume1.34M Price19.94
Recom2.70 SMA203.37% SMA5043.56% SMA20090.47% Volume735,166 Change0.15%
Jun-13-22Resumed Cantor Fitzgerald Overweight $46 → $21
Aug-02-21Initiated Craig Hallum Buy $58
Mar-31-21Reiterated H.C. Wainwright Buy $53 → $55
Feb-17-21Initiated Oppenheimer Outperform $60
Sep-08-20Initiated H.C. Wainwright Buy $53
Jul-14-20Initiated SVB Leerink Outperform $54
Jul-14-20Initiated Jefferies Buy $54
Jul-14-20Initiated Credit Suisse Outperform $64
Sep-07-22 12:37PM
Sep-02-22 10:09AM
Sep-01-22 04:10PM
02:36PM
09:55AM
09:21AM Loading…
09:21AM
09:01AM
08:31AM
08:18AM
08:12AM
08:00AM
Aug-18-22 09:36AM
Aug-05-22 07:00AM
Aug-03-22 08:14AM
Aug-02-22 04:01PM
07:05AM Loading…
Jul-29-22 07:05AM
Jul-12-22 07:05AM
Jul-08-22 09:55AM
Jun-30-22 07:05AM
Jun-22-22 09:55AM
Jun-15-22 09:55AM
Jun-13-22 02:45PM
Jun-10-22 07:22AM
Jun-03-22 07:05AM
May-26-22 07:05AM
May-08-22 10:56AM
May-06-22 07:05AM
Apr-29-22 07:05AM
Mar-01-22 07:05AM
Feb-23-22 07:05AM
02:38AM Loading…
Feb-17-22 02:38AM
Feb-08-22 07:05AM
Jan-13-22 07:05AM
Jan-07-22 07:05AM
Dec-30-21 10:00AM
Dec-28-21 05:38AM
Dec-16-21 07:05AM
Dec-13-21 11:06AM
Dec-11-21 09:30AM
Dec-09-21 07:05AM
Nov-30-21 07:05AM
Nov-24-21 06:54AM
Nov-19-21 08:00AM
06:32AM
Nov-18-21 10:14AM
Nov-12-21 07:05AM
Nov-05-21 07:05AM
Nov-04-21 09:05AM
Oct-07-21 07:05AM
Sep-17-21 07:05AM
Aug-13-21 07:05AM
Aug-06-21 07:05AM
Jul-27-21 08:05PM
Jun-17-21 05:10AM
Jun-14-21 07:05AM
Jun-11-21 02:13PM
07:05AM
May-20-21 07:05AM
May-17-21 07:05AM
May-14-21 07:05AM
06:15AM
May-06-21 07:05AM
Mar-30-21 11:08AM
07:20AM
07:05AM
06:15AM
Mar-23-21 04:05PM
Mar-03-21 08:50AM
Feb-17-21 07:05AM
Jan-20-21 07:05AM
Jan-11-21 07:05AM
Jan-07-21 07:05AM
Dec-19-20 03:11AM
Dec-15-20 04:35PM
Dec-10-20 10:53PM
06:34PM
Dec-08-20 04:15PM
Dec-07-20 04:30PM
Nov-12-20 07:05AM
Nov-10-20 07:05AM
Nov-04-20 01:11PM
07:05AM
Oct-26-20 07:05AM
Sep-20-20 10:40AM
Sep-15-20 07:05AM
Sep-09-20 07:05AM
Aug-13-20 07:05AM
Jul-30-20 07:05AM
Jul-02-20 07:30PM
Jun-23-20 04:05PM
Jun-18-20 09:04PM
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Patrick F.SVP, Chief Medical OfficerApr 08Option Exercise5.0515,00075,750104,884Apr 14 06:10 PM
Kelly Patrick F.SVP, Chief Medical OfficerFeb 23Sale9.785,24551,28364,884Feb 25 05:08 PM
Lee Frank D.President and CEOFeb 23Sale9.7817,981175,80979,769Feb 25 05:08 PM
Potts JeannetteSee RemarksFeb 23Sale9.784,67245,68022,358Feb 25 05:01 PM
Shegog ToddSVP, Chief Financial OfficerFeb 23Sale9.785,68755,60522,813Feb 25 05:04 PM